Erratum: Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study (Journal of Neurology (2014) 261 (267-276) DOI: 10.1007/s00415-013-7115-8);Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: A phase 3b, open-label study

Journal of Neurology

Volumn 261, Issue 2, 2014, Pages 267-276

  Gold, Ralf ^a   Comi, Giancarlo ^b   Palace, Jacqueline ^c   Siever, Arno ^d   Gottschalk, Rebecca ^e   Bijarnia, Mahendra ^f   Von Rosenstiel, Philipp ^e   Tomic, Davorka ^e   Kappos, Ludwig ^g  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF MILAN   (Italy)

^c OXFORD UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^d Urologische Gemeinschaftspraxis   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

^f Novartis Healthcare Pvt Ltd   (India)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Fingolimod; Multiple sclerosis; Safety; Tolerability

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; FINGOLIMOD;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; ASYMPTOMATIC DISEASE; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTRIC CONDUCTIVITY; ELECTROCARDIOGRAPHY; ELEVATED BLOOD PRESSURE; FATIGUE; FEMALE; HEADACHE; HEART DISEASE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; INCIDENCE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; OPEN STUDY; PATIENT MONITORING; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINUS BRADYCARDIA; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BRADYCARDIA; DISABILITY EVALUATION; ELECTROCARDIOGRAPHY; ENDPOINT DETERMINATION; FEMALE; HEART CONDUCTION SYSTEM; HEART DISEASES; HEART RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; PROPYLENE GLYCOLS; SPHINGOSINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84895445228     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-014-7280-4     Document Type: Erratum

References (18)

1. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, Foster CA, Zollinger M, Lynch KR (2002) The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 277(24):21453-21457 (Pubitemid 34952287)
2. European Medicines Agency (2011) Annex I. Summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR---Product-Information/human/002202/WC500104528.pdf. Accessed 8 October 2012
3. European Medicines Agency (2012) Revised summary of product characteristics. Gilenya (fingolimod). http://www.ema.europa.eu/ docs/en-GB/document-library/Other/2012/04/WC500125687.pdf. Accessed 8 October 2012
4. US Food and Drug Administration (2010) Gilenya prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/022527s002lbl.pdf. Accessed 8 October 2012
5. US Food and Drug Administration (2012) Gilenya (fingolimod): revised US prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2012/022527s008lbl.pdf. Accessed 8 October 2012
6. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan K, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, Malhotra M, von Rosenstiel P, Lublin FD (2012) Efficacy and safety of fingolimod in patients with relapsing-remitting multiple sclerosis (RRMS): Results from an additional 24-month double-blind, placebo-controlled study (FREEDOMS II Study). Neurology 78(suppl 1):P01.133
7. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L (2010) Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 362(5):402-415
8. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P (2010) A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 362(5):387-401
9. Koyrakh L, Roman MI, Brinkmann V, Wickman K (2005) The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am J Transpl 5(3):529-536 (Pubitemid 40313344)
10. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355(11):1124-1140 (Pubitemid 44394919)
11. ICH harmonized tripartite guideline-guideline for good clinical practice: E6(R1). Geneva: International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. http://www.ich.org/fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/ E6-R1/Step4/E6-R1--Guideline.pdf. Accessed 8 October 2012
12. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Ferney-Voltaire F. http://www.wma.net/en/ 30publications/10policies/b3/index.html. Accessed 8 October 2012
13. Polman C (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846
14. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444-1452
15. DiMarco J, O'Connor P, Cohen J, Reder A, Zhang-Auberson L, Tang D, Collins W, Kappos L (2012) Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies. Mult Scler 18(Suppl 4):55-227
16. Kovarik JM, Lu M, Riviere GJ, Barbet I, Maton S, Goldwater DR, Schmouder RL (2008) The effect on heart rate of combining single-dose fingolimod with steady-state atenolol or diltiazem in healthy subjects. Eur J Clin Pharmacol 64(5):457-463
17. Ontaneda D, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA (2012) Early tolerability and safety of fingolimod in clinical practice. J Neurol Sci 23:167-172
18. US Food and Drug Administration (2012) Gilenya (fingolimod): Drug safety communication-revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod). http://www.fda.gov/Drugs/ DrugSafety/ucm303192.htm. Accessed 8 October 2012